drugset / Trial / NCT07662031
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
25 enrolled
Washington University School of Medicine
Compass Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
Timeline
- Start
- 2026-08-31
- Primary completion
- 2030-08-31
- Completion
- 2032-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTX-009 | Unknown | 10 mg/kg | Intravenous |
| Background | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |